What is the ATE.TO share price today?

This page shows the latest available Antibe Therapeutics Inc. (ATE.TO) price with its change against the prior close. Values are delayed or previous-close, not real-time.

Where is Antibe Therapeutics Inc. listed?

Antibe Therapeutics Inc. trades on the Toronto Stock Exchange under the symbol ATE.TO, ISIN CA0370255097.

How large is Antibe Therapeutics Inc.?

Its market capitalisation is approximately 15.64M CAD, based on the latest available price and share count from our data provider.

Toronto Stock Exchange (TSX) · ATE.TO · ISIN CA0370255097

Antibe Therapeutics Inc.

No trading activity has been reported for this listing since April 8, 2024. It may be delisted, halted or inactive.

0.2950 CAD

April 8, 2024

Antibe Therapeutics Inc. (ATE.TO) trades on the Toronto Stock Exchange and operates in the Medical - Devices industry. Its market capitalisation is approximately 15.64M CAD. The company reports around 11 employees. Its ISIN is CA0370255097. This page shows the latest available price, the day and 52-week ranges and an interactive chart. Quotes are delayed and are not intended for order execution.

Key facts

Exchange

Toronto Stock Exchange (TSX)

ISIN

CA0370255097

Sector

Healthcare

Industry

Medical - Devices

Country

Market cap

15.64M CAD

Employees

Previous close

0.26 CAD

Day range

0.26 – 0.35

52-week range

0.15 – 1.23

Volume

167.04K

50-day average

0.70 CAD

200-day average

0.66 CAD

Asset type

Equity

About Antibe Therapeutics Inc.

Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.

Company website

Frequently asked

What is the ATE.TO share price today?: This page shows the latest available Antibe Therapeutics Inc. (ATE.TO) price with its change against the prior close. Values are delayed or previous-close, not real-time.
Where is Antibe Therapeutics Inc. listed?: Antibe Therapeutics Inc. trades on the Toronto Stock Exchange under the symbol ATE.TO, ISIN CA0370255097.
How large is Antibe Therapeutics Inc.?: Its market capitalisation is approximately 15.64M CAD, based on the latest available price and share count from our data provider.

All Antibe Therapeutics Inc. data comes from exchange and provider feeds for the Toronto Stock Exchange and is published for information, not as investment advice.

Real-time quotes are not licensed; prices are delayed or previous close, so they may lag the market by 15 minutes or a full session. Information only, not for trading. Where a figure is not covered by our licensed sources, the page says so rather than showing a substitute.